Breakthrough in Sarcoidosis Research: New Standardized Trial Endpoints Promise Better Treatment Outcomes

Can Standardized Endpoints Transform Sarcoidosis Trials?

Significant progress has been made in standardizing clinical trial endpoints for sarcoidosis, as a newly formed World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) task force has reached consensus on 13 key statements to guide future studies. The international group, comprising 55 experts from 12 countries including clinicians, industry representatives, and patients, has established recommendations for both pulmonary and cardiac sarcoidosis trials.

The task force addressed a critical gap in sarcoidosis research: the lack of standardized, clinically meaningful endpoints across clinical trials. Since 2000, 15 placebo-controlled trials have been completed using varied endpoints, with forced vital capacity (FVC) reported in 13 of 15 studies but no single endpoint common to all investigations. This inconsistency has complicated both trial design and regulatory approval processes.

How Will New Endpoint Strategies Impact Trial Design?

"Clinical trial endpoints should be designed by a team of clinical researchers, patients, and industry representatives," notes the task force's first consensus statement, emphasizing that endpoint selection should be driven by "feasibility, safety, sample size consideration, usefulness for regulatory approval and ability to recruit patients." For steroid-dependent pulmonary sarcoidosis patients, the group identified three key endpoints: FVC, Kings Sarcoidosis Questionnaire (KSQ), and prednisone reduction.

A significant recommendation from the group is that changes in FVC, KSQ, and prednisone dosage should be analyzed as continuous variables rather than categorical thresholds. This approach prevents information loss, improves statistical power, and reduces both type I and type II errors. For prednisone reduction specifically, the task force endorsed including "the proportion of patients achieving total discontinuation or reduction to a daily prednisone dose of 5 mg or less" as a meaningful endpoint.

The task force also validated composite endpoints, particularly time to clinical worsening (TCW), which may include "sarcoidosis related hospitalization, death, or transplantation, or increase in prednisone dose for sarcoidosis for more than two weeks or 10% or greater decrease in FVC% predicted or an eight-point or greater decrease in KSQ-Lung scale on two consecutive measurements." This approach mirrors successful endpoint strategies in other progressive conditions.

Concerns about corticosteroid toxicity have become increasingly central to endpoint selection. An international survey of 1911 patients from 34 countries revealed that patients who had ever received oral corticosteroids for sarcoidosis experienced significantly higher odds (range 1.9-3.8) of developing complications including diabetes, hyperlipidemia, osteoporosis, and infections. The Glucocorticoid Toxicity Index (GTI) has emerged as a valuable tool for quantifying reduction in steroid exposure during clinical trials and could support regulatory applications for medication approval.

For cardiac sarcoidosis, the group acknowledged that no single endpoint suits all trials due to varying populations and goals. However, they endorsed PET as the preferred advanced imaging modality, with the specific PET variable dependent on trial context. The consensus recommended that if an imaging endpoint is selected as primary, a clinical secondary endpoint should be included to broaden efficacy evaluation and identify potential adverse effects.

What Do Leading Experts Reveal About Patient Outcomes?

Dr. Robert Baughman, one of the task force leaders, explained, "The goal of the current task force is to update the status of clinical trial endpoints which can provide a pathway for future trial design incorporating the concept of patient feels, functions, and survives."

Health-related quality of life (HRQoL) has gained prominence as a potential primary or key secondary endpoint. In a recent Delphi survey, experts ranked HRQoL as the most important endpoint in clinical trials, with the KSQ as the preferred instrument. However, further validation to regulatory standards is needed before HRQoL measures can serve as primary endpoints in Phase 3 trials.

Are Ongoing Trials Shaping the Future of Sarcoidosis Treatment?

Currently, multiple pharmaceutical companies including aTyr (NCT05415137), Kinevant (NCT05314517), and Xentria (NCT05890729) have ongoing or recently completed trials using steroid withdrawal, KSQ-Lung, and FVC % predicted as primary and/or secondary endpoints. The results of these trials will further validate these endpoints and potentially shape future regulatory decisions.

The task force also identified areas for future research, including the validation of impedance oscillometry as a potential endpoint, further validation of health-related quality of life instruments, and objective cough counting. As these measures become more standardized, they could provide additional tools for assessing treatment efficacy in this complex disease.

Industry Context: This consensus marks a significant advancement for drug development in sarcoidosis, providing clearer pathways for companies to design approvable clinical trials. The standardization of endpoints will likely accelerate development programs and reduce regulatory uncertainty, potentially attracting more investment to this historically challenging therapeutic area. The focus on steroid-sparing endpoints also aligns with broader industry trends toward reducing long-term corticosteroid exposure across multiple inflammatory conditions, reflecting both patient preferences and evolving clinical practice.

Summary

The WASOG task force has achieved consensus on 13 key statements for standardizing sarcoidosis clinical trial endpoints. The initiative addresses the historical lack of consistency in trial measurements by establishing three primary endpoints for steroid-dependent pulmonary sarcoidosis: forced vital capacity (FVC), Kings Sarcoidosis Questionnaire (KSQ), and prednisone reduction. The task force recommends analyzing these endpoints as continuous variables rather than categorical thresholds. For cardiac sarcoidosis, PET scanning is endorsed as the preferred imaging modality. The consensus emphasizes the importance of reducing corticosteroid exposure due to associated complications and validates composite endpoints, particularly time to clinical worsening. This standardization is expected to streamline drug development and regulatory approval processes, with several pharmaceutical companies already implementing these endpoints in ongoing trials.